文献速递新发突发、热带与寄生虫病

进行性多灶性白质脑病患者血浆JC病毒DNA的诊断与预后价值

Diagnostic and Prognostic Value of JC Virus DNA in Plasma in Progressive Multifocal Leukoencephalopathy.
PubMed 文献 · Clin Infect Dis · 2018-01-01

该回顾性研究分析了103例进行性多灶性白质脑病患者及144例对照的血浆JC病毒(JCV)DNA,发现血浆JCV-DNA诊断PML的敏感度为48%、特异度为97%,且其水平与脑脊液水平和既往皮质类固醇治疗独立相关,在HIV阴性及接受cART的HIV阳性患者中较高血浆JCV-DNA水平与疾病进展相关。

要点

  • 血浆JCV-DNA诊断PML的敏感度为48%、特异度为97%,在HIV阴性者中分别为83%和100%。
  • 16例脑脊液JCV-DNA阴性的PML患者中,4例(25%)血浆JCV-DNA可检出。
  • 血浆JCV-DNA水平与脑脊液水平独立相关(P < .0001),并与既往皮质类固醇治疗相关(P = .012)。

核心结论

  • 检测血浆JCV-DNA可能补充PML诊断,尤其在脑脊液不可获得或脑脊液中JCV-DNA不可检出时。
  • 血浆JCV-DNA水平可能作为HIV阴性和接受cART治疗的HIV阳性PML患者疾病进展的标志物。

研究设计与样本

  • 回顾性分析PML患者发病附近采集的血浆样本及无PML对照的血浆样本。
  • 共纳入103例PML患者和144例无PML对照。

主要发现

  • 血浆JCV-DNA在49/103(48%)PML患者中检出(HIV阴性20/24,83%;HIV阳性29/79,37%),在4/144(3%)对照中检出(HIV阴性0/95;HIV阳性4/49,8%)。
  • 诊断敏感度和特异度分别为48%和97%(HIV阴性83%和100%;HIV阳性37%和92%)。
  • 16例脑脊液JCV-DNA不可检出的PML患者中,4例(25%)血浆JCV-DNA可检出。
  • 血浆JCV-DNA水平与脑脊液水平独立相关(P < .0001),并与既往皮质类固醇治疗相关(P = .012)。
  • 较高血浆JCV-DNA水平与HIV阴性患者疾病进展相关(P = .005);在HIV阳性患者中,仅在接受cART治疗者中与进展风险增加相关(P < .0001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease caused by the polyomavirus JC (John Cunningham; JCV) that affects patients with impaired immune systems. While JCV-DNA detection in cerebrospinal fluid (CSF) is diagnostic of PML, the clinical significance of plasma JCV-DNA is uncertain. METHODS: We retrospectively analyzed plasma samples from PML patients that were drawn close to disease onset and from controls without PML. In PML patients, we compared plasma JCV-DNA detection and levels to clinical and laboratory parameters, and patient survival. RESULTS: JCV-DNA was detected in plasma of 49/103 (48%) patients with PML (20/24, 83%, human immunodeficiency virus [HIV] negative; 29/79, 37%, HIV-positive) and of 4/144 (3%) controls without PML (0/95 HIV-negative; 4/49, 8%, HIV-positive), yielding a diagnostic sensitivity and specificity of 48% and 97% (83% and 100% in HIV-negative; 37% and 92% in HIV-positive), respectively. Among 16 PML patients with undetectable CSF JCV-DNA, 4 (25%) had detectable plasma JCV-DNA. Plasma JCV-DNA levels were independently associated with CSF levels (P < .0001) and previous corticosteroid treatment (P = .012). Higher plasma JCV-DNA levels were associated with disease progression in HIV-negative patients (P = .005); in HIV-positive patients, there was an increased risk of progression only in those treated with combination antiretroviral therapy (cART; P < .0001). CONCLUSIONS: Testing JCV-DNA in plasma might complement PML diagnosis, especially when CSF is unavailable or JCV-DNA not detectable in CSF. In addition, JCV-DNA plasma levels could be useful as a marker of disease progression in both HIV-negative and cART-treated, HIV-positive PML patients.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ferretti F, Bestetti A, Yiannoutsos CT, et al. Diagnostic and Prognostic Value of JC Virus DNA in Plasma in Progressive Multifocal Leukoencephalopathy. Clin Infect Dis. 2018. PMID: 29346632. doi:10.1093/cid/ciy030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。